Thérapeutiques et prise en charge de la sclérose en plaques

Brochet, Bruno; Lebrun-Frénay, Christine; Sèze, Jérôme De; Zephir, Hélène; Allart, Étienne; Audoin, Bertrand; Ayrignac, Xavier; Bensa, Caroline; Blanchard-Dauphin, A.; Brassat, David; Clavelou, Pierre; Cohen, M.; Créange, Alain; Collongues, Nicolas; Debouverie, Marc; Defer, Gilles; Sèze, M. de; Donzé, C.; Edan, Gilles; Fromont, Agnès; Gamé, X.; Gout, Olivier; Guillon, C.; Harand, Caroline; Jenny, B.; Labauge, Pierre; Lalive, Patrice H.; Page, Emmanuelle Le; Marqué, P.; Michel, Laure; Moisset, Xavier; Ouallet, J.-C.; Outteryck, Olivier; Pelé, F.; Pelletier, Jean; Pittion‐Vouyovitch, S.; Ramelli, Anne-Laure; Ruet, Aurélie; Thouvenot, Éric; Veillard, D.; Vignal-Clermont, C.; Vukusic, Sandra

doi:10.1016/b978-2-294-75020-5.00016-8

Cited by 1 publication

(1 citation statement)

References 360 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Numerous disease-modifying therapies (DMTs) are available. 3 The French National Authority for Health authorized four therapeutic classes of first-line treatments in relapsing-remitting MS. 4 Offering a more efficacious drug is recommended when patients showed evidence of clinical and/or radiological activity, particularly when patients are receiving first-line treatments. 5 However, these partial guidelines are restricted to patients treated by interferon-β (IFN-β) or glatiramer acetate and based on the comparison between the switch to another first-line DMT and the switch to second-line DMT.…”

Section: Introductionmentioning

confidence: 99%

Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression. Objective: We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy. Methods: Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs). Results: From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09–0.22) for the waiting group and 0.40 (95% CI 0.32–0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30–0.46) and 0.44 (95% CI 0.37–0.52), respectively. Conclusions: By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse.

show abstract